The oviduct contributes to the reproductive environment by secreting various factors, including a family of glycoproteins termed oviductins. Although many studies have demonstrated that ovarian hormones modulate oviductin gene expression in several mammalian species, there has been controversy surrounding the regulation of golden hamster oviductin. The current study was undertaken to investigate the transcriptional and translational modifications of hamster oviductin during the estrous cycle. First, we verified that hamster oviductin mRNA expression remains constant throughout the estrous cycle by semiquantitative reverse transcription polymerase chain reaction. We then developed a polyclonal antibody against recombinant hamster oviductin (rhaOv m ). The anti-rhaOv m antibody was subsequently used in conjunction with quantitative immunocytochemistry to investigate the oviductin levels in the hamster oviduct during the estrous cycle. Quantification of immunolabeling revealed a high, consistent level of glycoprotein throughout the estrous cycle. Therefore, it appears that the production of oviductin is not regulated differentially during the estrous cycle. Size variations in hamster oviductin expression were also investigated by Western blot analysis. The oviduct contains several forms of oviductin at each stage of the estrous cycle, the native glycosylated form(s) of 160-350 kDa, and several precursor forms of 70-100 kDa. Although variations in the intensities of the polydispersed band were not evident during the estrous cycle, additional bands ranging from 90 to 100 kDa were detected in the estrus, metestrus, and diestrus 1 stages. The results from the present investigations suggest that whereas ovarian hormones do not appear to influence the hamster oviductin mRNA and protein expressions, glycosylation of hamster oviductin appears to be differentially regulated during the estrous cycle.
INTRODUCTION
Many important phenomena of mammalian reproduction occur within the female reproductive tract, especially within the oviduct. The mammalian oviduct is a very active secretory organ, providing the optimal milieu for the suc- cessful occurrence of sperm capacitation, fertilization, and early embryonic development [1] . The nonciliated epithelial cells of the oviduct actively synthesize and secrete a high-molecular-weight family of glycoproteins termed oviductins [1] . These oviduct-specific proteins have been described in many species, including the hamster [2, 3] .
There are several proposed functions for oviductins, which include increased viability and motility of spermatozoa within the female reproductive tract [4] as well as increased sperm capacitation and fertilizing capabilities [5] . The presence of oviductin has been shown to increase sperm-egg binding and penetration rates [6] [7] [8] and decrease polyspermy [8, 9] . Oviductin also appears to increase cleavage rates of embryos [9, 10] and the number of embryos reaching the blastocyst stage [8, 10] . Therefore, the presence of oviductins within the oviductal lumen at the time of these events would be beneficial.
Ovarian steroids have been proposed to modulate the expression of oviductins in human [11] [12] [13] , baboon [12, 14, 15] , sheep [16, 17] , cow [18, 19] , and pig [20, 21] . Previous immunocytochemical studies carried out in our laboratory using a monoclonal antibody specific for a glycosidic epitope of hamster oviductin revealed a variation in protein levels during the estrous cycle [22] . The concentration of oviductin appeared to be highest during the stage of estrus and decreased to reach a minimum at diestrus 2 before beginning to increase again at proestrus. The maximum amount of oviductin observed at estrus coincides with the time of ovulation [22] . However, previous studies have also revealed that hamster oviductin mRNA expression levels do not vary significantly during the estrous cycle [23, 24] . Nevertheless, there appears to be some degree of control over regulation of oviductin mRNA and protein expressions in most mammalian species.
In view of these findings, it is hypothesized that there are estrous cycle-associated modifications in the production of hamster oviductin by the oviductal epithelium. The objective of the current study was to further investigate the regulation of oviductin gene expression during the estrous cycle. Initially, we attempted to verify the regulation of hamster oviductin mRNA expression during the estrous cycle by semiquantitative reverse transcription polymerase chain reaction (RT-PCR). Subsequently, we produced a recombinant hamster oviductin (rhaOv m ) from a cDNA clone (phage-19) [23] coding for the mucin domain of hamster oviductin and used the recombinant peptide to generate a polyclonal antibody (anti-rhaOv m antibody). The production of the anti-rhaOv m antibody against a peptide portion of hamster oviductin differs from previously used monoclonal antibodies that recognize glycosidic epitopes attached to the protein backbone [2, [25] [26] [27] [28] [29] [30] . In the present study, we have applied quantitative immunocytochemistry using the anti-rhaOv m antibody to localize and quantify the corresponding glycoprotein in the secretory granules of the nonciliated cells of the oviductal epithelium. The quantitative immunocytochemical data were complemented by Western blot analysis to examine the size variations in the protein expression of oviductin in the hamster oviduct during the estrous cycle. The present results, taken together with previous findings obtained in our laboratory by use of quantitative immunocytochemistry [22] and lectin cytochemistry [31] , indicate that glycosylation of hamster oviductin is temporally and differentially regulated during the estrous cycle.
MATERIALS AND METHODS

Animals
Female golden hamsters (Mesocricetus auratus), 6-8 wk of age (Charles River Inc., St. Constant, QC, Canada), were housed in a temperature-controlled room with a 12L:12D cycle (lights on at 0600). The animals were analyzed for mucous vaginal discharge indicative of the metestrus stage of the estrous cycle and were cycled for 2-3 wk to establish regularity of the cycle. The animals were separated into groups according to the five different stages of the cycle [22] . All animal care practices and experimental procedures complied with the guidelines of the Canadian Council on Animal Care and were approved by the University Animal Use Committee at both Queen's University and the University of Montreal.
Semiquantitative Reverse Transcription Polymerase Chain Reaction
Semiquantitative RT-PCR was performed to examine relative changes in oviductin mRNA expression during the estrous cycle. Oviducts from at least four animals per stage were pooled and homogenized to obtain total messenger RNA representative of each stage of the estrous cycle. Messenger RNA was extracted using Sigma TRI-reagent according to the manufacturer's instructions (Sigma-Aldrich, Oakville, ON, Canada). For reverse transcription, mRNA was subjected to first strand cDNA synthesis using the Omniscript Reverse Transcriptase kit (Qiagen, Mississauga, ON, Canada) according to the manufacturer's instructions.
PCR for oviductin semiquantitative mRNA analysis was performed using the sense primer 5Ј-GACCTGGCTCTGAGAGTCTT-3Ј and the antisense primer 5Ј-CACTGTGGCTGTGATCTGTC-3Ј. The primers were designed to correspond to a region coding for the mucin domain of hamster oviductin, nucleotides 1175-1713 of the published sequence [23] . The length of the amplified region was 538 base pairs (bp). Changes in PCR products of the oviductin gene were evaluated by comparison with those for the internal standard, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using GAPDH sense primer 5Ј-ACCACAGTCCATGCCATC-3Ј and antisense primer 5Ј-CCTGCTTCACCACCTTCT-3Ј. The primers were designed within the nucleotide sequence of the golden hamster GAPDH gene [32] . The length of the amplified region was 267 bp. PCR mixtures containing 1ϫ buffer (Qiagen), 2.5 mM MgCl 2 , 200 M dNTP mix, 2.5 U Taq DNA polymerase (Qiagen), 0.5 pM selected primers, and sterile H 2 O were prepared. Amplifications were performed using the following conditions: denaturation at 94ЊC for 30 sec, annealing at 61ЊC for 30 sec, and elongation at 72ЊC for 1 min. A final elongation step was performed by incubation at 72ЊC for 10 min. Twenty-two cycles were performed for the amplification of oviductin and 32 cycles for GAPDH to ensure that the amplification of each gene was in the linear range and not during the plateau phase. PCR products were separated on a 1.0% agarose gel containing 0.5 g/ml ethidium bromide. The separated PCR products were photographed under UV light. Semiquantitative analysis was conducted by comparing relative band intensities of oviductin normalized by comparison with GAPDH using SigmaGel software (Jandel Scientific, San Rafael, CA). One-way ANOVA was used for analyzing differences in bands intensities of oviductin products across the five stages of the estrous cycle. Statistical values of P Ͻ 0.05 were considered significant.
Cloning of cDNA to Mucin Domain of Hamster Oviductin and Production of rhaOv m
A hamster oviductin cDNA clone (phage-19) [23] was digested with Apa I and EcoR I, producing a fragment designated as haOv m (nt 1140-2276 of the whole cDNA) and coding for the mucin domain of the protein [33] . The nucleotide sequence of the haOv m fragment is unique to hamster oviductin and does not resemble any other glycoproteins. The expression vector pQE-32 (Qiagen) was digested with Sma I. The haOv m fragment and the digested vector were treated with T 4 DNA polymerase and ligated using T 4 DNA ligase at room temperature for 16 h. The haOv m fragment was cloned in frame with the 6xHis-tag of pQE-32 yielding the plasmid pQE-32-haOv m . The vector-haOv m junction was sequenced by the Sanger method [34] using the Sequenase 2.0 kit (U.S.B., Cleveland, OH). This construct was employed to transform Escherischia coli strain M15 using standard protocols [35] . At a cell density corresponding to A 600 ϭ 0.7-0.9 arbitrary units (AU), the expression of recombinant hamster oviductin (rhaOv m ) was induced by the addition of isopropyl-␤-D-thiogalactopyranoside (IPTG). The transformed cells were incubated for 3 h, harvested by centrifugation, resuspended in lysis buffer (8 M urea, 0.1 M NaH 2 PO 4 , 0.01 M Tris-HCl, pH 8.0), and then incubated overnight at 4ЊC with shaking.
The lysate was centrifuged, and the supernatant was loaded onto a Ni-NTA column (Qiagen). The column was washed until A 280 was less than 0.01 AU, and the bound peptide was eluted and lyophilized according to the manufacturer's instructions. The rhaOv m peptide was resuspended in distilled water.
Production of Antibodies Against rhaOv m
The rhaOv m peptide (5 g) was analyzed by SDS-PAGE on a 12% polyacrylamide gel followed by staining of the gel with Coomassie Blue. The portion of the gel corresponding to a molecular weight of ϳ43 kDa was cut and electroeluted (Electro-eluter model 422; Bio-Rad, Mississauga, ON, Canada). For immunization, a male white rabbit (Charles River) received multisite intradermal injections initially with 1 mg of rhaOv m dissolved in PBS and emulsified in complete Freund adjuvant (1:1, v/v). Subsequent booster injections were administered at 4-wk intervals with 1.0, 0.5, and 0.6 mg of the immunogen in PBS emulsified with an equal volume of incomplete adjuvant. Blood samples were collected 2 wk after each booster injection, and serum antibody titers were analyzed by ELISA and Western blot analysis. Controls were performed with the serum of a normal rabbit.
The IgG fractions of the immune and control sera were purified with Affi-Gel protein A agarose beads as described by the manufacturer (AffiGel Protein A Kit; Bio-Rad). After protein A purification, the IgG fractions of the immune and control sera were further affinity purified using AffiGel 15 resin (Bio-Rad) coupled with rhaOv m according to the manufacturer's instructions. The specificity of the affinity-purified anti-rhaOv m antibody was established by Western blot analysis. Briefly, 5 g of rhaOv m peptide were separated by SDS-PAGE [36] , transferred to a polyvinylidene difluoride (PVDF) membrane [37] , and immunodetected with diluted antirhaOv m antibody (0.8 mg/ml; 1:1000; 1:5000). Control experiments were performed using 5 g recombinant dehydrofolate reductase (DHFR; which also contains six histidine residues) to determine whether the histidine residues are immunogenic. The anti-rhaOv m antibody was found not to react with recombinant DHFR. Total protein samples from the ovary, oviduct, and uterus (5 g total protein) were also examined to test the tissue specificity of the anti-rhaOv m antibody.
Quantitative Immunocytochemistry
Twenty female golden hamsters (Charles River), 6-8 wk of age, were used for this study. The animals were killed by cervical dislocation according to the timing of the different stages of the estrous cycle [38] . Oviducts were excised and processed for immunocytochemistry as described previously [22] . Ultrathin sections of cycled hamster oviduct were immunolabeled as described previously [22] using the anti-rhaOv m antibody (0.8 mg/ml) diluted 1:5 in PBS. Colloidal gold particles of 8 nm diameter [39] were used for preparation of the protein A-gold complex according to the method previously described [40] . Sections were incubated with the protein A-gold complex diluted 1:10 in PBS. The sections were counterstained with uranyl acetate and lead citrate before examination on a Hitachi 7000 Electron Microscope (Hitachi Canada, Ltd., Missisauga, ON, Canada). To assess the specificity of the anti-rhaOv m antibody, control experiments were performed with preimmune serum (diluted 1:5 in PBS). All other steps and conditions remained the same.
The labeling densities of gold particles over the secretory granules were evaluated on electron micrographs, enlarged 31 200 times. For each of the five stages of the estrous cycle, the surface area of each granule and the number of gold particles were determined using a Carl Zeiss MOP-3 modular system (Carl Zeiss, Canada, Ltd., Toronto, ON, Canada). For 
evaluated. The data were examined using a oneway ANOVA statistical investigation.
Isolation of Total Protein from Oviductal Tissue
The oviducts used for isolation of total protein were collected from 15 mature cycling hamsters divided into groups of three animals each, according to the five stages of the estrous cycle. The oviducts were homogenized, and total protein was prepared as described previously [41] . The total protein contents of the homogenized oviducts were evaluated using the Bio-Rad Protein Assay (Bio-Rad) with bovine serum albumin (BSA) as the protein standard.
SDS-PAGE, Transfer, and Immunodetection of Hamster Oviductin
Oviduct protein samples containing 10 g total protein from each stage of the estrous cycle were prepared and separated by SDS-PAGE under reducing conditions as described by Laemmli [36] . The proteins were transferred to a PVDF membrane according to the procedure described by Towbin et al. [37] . After transfer of proteins, the membrane was blocked with 10% BSA in 10 mM TBS buffer (pH 8.0) followed by incubation with diluted anti-rhaOv m antibody (0.8 mg/ml; 1:1000 in TBS) for 1 h. The membrane was washed in tris-buffered solution plus Tween 20 (TBST) buffer prior to incubation with the alkaline phosphatase-conjugated goat anti-rabbit IgG (1:10 000) for 1 h. For chemiluminescence detection, the membrane was equilibrated in detection buffer followed by development with CSPD (disodium 3-(4-methoxyspiro{1,2-dioxethane-3,2Ј-(5Ј-chloro)tricyclo[3,3.1.1 3, 7 ]decan}-4-yl) phenyl phosphate) (Roche Diagnostics, Laval, QC, Canada). In order to examine differences in protein expression of the fully glycosylated, mature form of oviductin during the estrous cycle, changes in protein levels of the polydispersed band (160-350 kDa) were normalized by comparison with those of an internal standard, ␤-actin. After analysis for hamster oviductin, the blots were washed twice with TBST for 10 min and immunodetected for ␤-actin using the monoclonal anti-␤-actin antibody (1:20 000 in TBST; Sigma) according to the procedure recommended by the supplier. The immunoreaction was developed using Western Lightnin Chemiluminescence Reagent Plus (Perkin-Elmer, Woodbridge, ON, Canada). Quantitative analysis was performed on three separate blots and conducted by comparing band intensities of oviductin normalized to ␤-actin using SigmaGel Software (Jandel). One-way ANOVA was used for analyzing differences in protein expression during the estrous cycle, and values of P Ͻ 0.05 were considered to be significant.
RESULTS
Examination of Gene Expression of Hamster Oviductin During the Estrous Cycle
In order to examine the gene expression of oviductin during the estrous cycle, semiquantitative RT-PCR using oviductin-specific primers was performed. Oviductin mRNA was expressed by the hamster oviduct throughout the estrous cycle (Fig. 1a) . The relative band intensities of oviductin were compared with the internal control of GAPDH (Fig. 1b) . Statistical analysis revealed that the differences in the relative concentration of oviductin/GAPDH between the five stages of the estrous cycle were not statistically significant (P Ͼ 0.100).
Development of a Polyclonal Antibody Raised Against Recombinant Hamster Oviductin
In order to further investigate the translational modification of hamster oviductin, we then proceeded to develop a polyclonal antibody against recombinant hamster oviductin. A cDNA clone of hamster oviductin [23] was digested to produce a fragment, designated haOv m . The fragment was cloned into a pQE-32 vector, and the plasmid pQE-32-haOv m was used to transform M15 E. coli cells. Escherischia coli lysate was analyzed for recombinant oviductin expression by SDS-PAGE. Following electrophoresis, the presence of a new peptide, designated rhaOv m , was observed on induction of the M15 cells with IPTG (Fig. 2) . This new peptide migrated to a molecular weight of 43 kDa corresponding to the predicted mass based on the size of the cDNA fragment, haOv m (Fig. 2a) . The rhaOv m peptide was used to immunize a male white rabbit in order to produce a polyclonal antibody against hamster oviductin. The highest titers were obtained after the third booster injection as measured by ELISA and Western blot (results not shown). The anti-rhaOv m antibody was purified first on a protein A agarose column followed by affinity purification. By Western blot, a positive reaction with rhaOv m was obtained with the protein A-purified IgG fraction at a dilution as low as 1/100 000 and at a dilution of 1/5000 with affinity purified antibody (Fig. 2b) . Similar results were obtained by ELISA (not shown). The newly developed antibody reacted with total protein samples from the oviduct but not with total protein samples from the ovary or uterus, indicating the tissue specificity of the anti-rhaOv m antibody (results not shown).
Immunocytochemical Detection of Oviductin in the Hamster Oviduct During the Estrous Cycle
To examine immunoreactivity in the secretory granules of the nonciliated oviductal cells, a quantitative immunocytochemical study was performed. The application of antirhaOv m antibody to thin sections of Lowicryl-embedded hamster oviduct, followed by incubation with protein Agold complex, resulted in a specific labeling. As all five stages of the estrous cycle presented a similar labeling pattern, only the representative estrus stage is presented here. Within the nonciliated secretory cells of the oviductal epithelium, labeling was observed over the content of the secretory granules located in the apical portion of the cells (Fig. 3a) as well as those positioned adjacent to the Golgi region. The ciliated cells of the epithelium were not labeled with the anti-rhaOv m antibody (not shown). Therefore, the labeling specificity of the anti-rhaOv m antibody for oviductin was established. For the purpose of quantitation, emphasis has been placed on the immunolabeling for oviductin in the secretory granules. Control sections of hamster oviduct incubated with preimmune serum followed by labeling with protein A-gold complex resulted in very few, randomly distributed gold particles over the oviductal sections (Fig.  3b) .
Quantitative Evaluation of Immunogold Labeling
In order to evaluate the labeling density of oviductin within the secretory granules of the nonciliated cells, particular consideration was directed toward the number of gold particles located within the granules of oviducts at each of the five stages of the estrous cycle. Only the granules located in the apical portion of the cells were counted, as these are considered to be mature in nature and ready to release their contents into the lumen of the oviduct. The labeling density of oviductin over the secretory granules (Fig. 4) indicated that there were no significant differences (P Ͼ 0.05) among the five experimental groups (corresponding to the five stages of the estrous cycle). The labeling densities of gold particles over the secretory granules in the control groups were negligible (results not shown).
Examination of Protein Expression of Hamster Oviductin During the Estrous Cycle
The protein levels of hamster oviductin in the oviduct were examined during the estrous cycle. The protein was detected in the oviductal protein lysates from all stages of the estrous cycle. The anti-rhaOv m antibody reacted with a broad band, ranging from approximately 160 to 350 kDa, corresponding to native form of oviductin (Fig. 5) . The antibody was also immunoreactive with several bands ranging between 70 and 90 kDa. In addition to the bands common to all five stages of the estrous cycle, a number of extra bands were repeatedly detected in subsequent experiments at the stages of estrus, metestrus, and diestrus 1 but not found in diestrus 2 and proestrus. Statistical analysis re-vealed that the relative intensity of the high-molecularweight polydispersed band of hamster oviductin for each of the five stages of the estrous cycle, after normalization to ␤-actin, was not significantly different from each other (P Ͼ 0.100) (results not shown).
DISCUSSION
In the present study, semiquantitative RT-PCR revealed that there were no significant differences in the relative mRNA concentrations of hamster oviductin between the five stages of the estrous cycle. This technique was utilized in order to verify observations of earlier studies in which less sensitive methods were used. The present findings are consistent with results obtained in previous studies investigating mRNA expression in the hamster by Northern blot analysis [24] and RNase protection assay [23] and provide further evidence that hamster oviductin mRNA expression does not change significantly during the estrous cycle in the hamster. It has been suggested that variation in hamster oviductin concentration during the estrous cycle is controlled at the translational and/or posttranslational level [23] .
Hamster oviductin was detected and quantified in the secretory granules of the nonciliated oviductal cells at each stage of the estrous cycle by use of quantitative immunocytochemistry in conjunction with the anti-rhaOv m antibody. The intracellular localization of hamster oviductin within the hamster oviductal epithelium is consistent with findings from previous studies utilizing a monoclonal antibody [2, 22] . Quantification of immunogold particles revealed a high, consistent labeling density over the secretory granules at each of the five stages of the estrous cycle. Statistical analysis, however, indicated that there were no significant differences in labeling density between the five stages, suggesting that the production of oviductin is not differentially regulated during the estrous cycle.
The present results provide new information regarding the biochemical properties of hamster oviductin. In an earlier quantitative immunocytochemical study carried out in our laboratory [22] , a maximal labeling for oviductin was observed at the stage of estrus corresponding to the time of ovulation. It was then concluded that the production of hamster oviductin is hormonally regulated [22] . The differences observed between the results obtained in the present study and those from the previous study [22] can be explained as follows: The monoclonal antibody used in our earlier study recognizes the fully glycosylated, native form of hamster oviductin [42] . The newly developed antirhaOv m antibody used in the current study recognizes epitopes located on the polypeptide and should therefore be able to detect the nascent, partially glycosylated and mature forms of hamster oviductin. Therefore, based on our data obtained in the present study using semiquantitative RT-PCR, quantitative immunocytochemistry, and Western blot analysis, taken together with our previous findings obtained with a monoclonal antibody [22] and lectin cytochemistry [31] , it is reasonable to speculate that ovarian hormones that fluctuate during the estrous cycle regulate glycosylation of hamster oviductin.
From all the information available to date, the mRNA and protein expressions of oviductin in several species appear to be dependent on the stage of the estrous or menstrual cycle. For example in humans, both mRNA [12, 13] and protein [11] expressions of oviductin are high during the periovulatory phase but are markedly reduced or nondetectable at other stages of the menstrual cycle. However, studies of oviductin in several mammalian species including the hamster indicate a difference in the regulation of oviductin expression between species with long durations of the estrous cycle and those with a relatively short cycle (i.e., rodents) [1] . It appears that individual species have developed their own mechanism of control over oviductin expression, whether it occurs at the transcriptional, translational, or posttranslational level.
In the present study, a number of bands were observed at different stages of the estrous cycle: A higher-molecularweight polydispersed band ranged from ϳ160 to 350 kDa, and several lower-molecular-weight bands were detected with approximate sizes of 70-100 kDa. The larger band corresponds to the highly glycosylated form of the protein having a molecular size of 160-350 kDa as previously reported [26, 41, 43] . The molecular size of the protein core has been estimated to be 70.89 kDa [44] ; therefore, the lower-molecular-weight bands observed in the present study are most likely due to the presence of the nascent protein and partially glycosylated forms of oviductin. In the present study, quantitative analysis of the Western blots failed to demonstrate any significant differences in band intensities between the five stages of the estrous cycle, likely because of the extensive glycosylation of hamster oviductin as revealed by the high-molecular-weight polydispersed band. Western blot analysis does not appear to be as sensitive as quantitative immunocytochemistry, which revealed the maximum labeling of hamster oviductin at estrus when a monoclonal antibody recognizing a carbohydrate epitope was used [22] . Nonetheless, additional bands with molecular weights of approximately 90-100 kDa were observed at the stages of estrus, metestrus, and diestrus 1. These additional bands may indicate stage-specific glycosylation occurring around the time of ovulation. A previous study employing 2D gel electrophoresis has reported the presence of two isoforms in the polydispersed, highly glycosylated band of hamster oviductin [41] . It will be interesting and important to determine in future studies whether glycosylation of one or both of these two isoforms is differentially regulated during the estrous cycle.
In order to fully comprehend the molecular, biochemical, and functional properties of oviductin, further studies must be undertaken. For example, investigation into the glycosyltransferase activity within the hamster oviductal epithelium during the estrous cycle may provide further insight into the regulation of posttranslational glycosylation of hamster oviductin. Although results from a previous study showed a cyclical variation in glycosyltransferase activity within oviductal fluid during the estrous cycle [45] , further study is required to determine the source of these enzymes and their relation to posttranslational modifications of hamster oviductin. Perhaps regulation over glycosylation of oviductin is required for the protein to exert its full function during the early processes of the reproductive process. Abnormal glycosylation of oviductin may lead to the inability of oviductin to perform its specific roles, resulting in certain mishaps during the processes of fertilization and/or early embryo development.
